| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514580000 | Thioureas (i.e., N-C(=S)-N | 15 |
| 20080207760 | Pharmaceutical Compositions For and Methods of Inhibiting Hcv - The present invention relates generally to replicase complex defect inducers and pharmaceutical compositions containing such inducers. Methods of developing mutants that are resistant to replicase complex defect inducers are also provided. Further included are mutants that can be used in screening for replicase complex defect inducers. Methods of screening test compounds for the ability to induce the formation of replicase complex defects are also described. Also included are methods of inhibition of HCV replication by replicase complex defect inducers. | 08-28-2008 |
| 514581000 | Thiocarbazides or thiosemicarbazides (i.e., N-N-C(=S)-N containing) | 1 |
| 514582000 | Thiocarbazones or thiosemicarbazones (i.e., C=N-N-C(=S)-N containing) | 1 |
| 514583000 | Benzene ring containing | 1 |
| 20150126610 | REDOX-DIRECTED CHELATORS TARGETING INTRACELLULAR METAL IONS - The present invention provides redox-activated chelators and methods for using the same to treat cancer. In one particular embodiment, the redox-activated chelator is of the formula: | 05-07-2015 |
| 514584000 | C=O, sulfur or cyano attached directly to thiourea nitrogen by nonionic bonding | 3 |
| 20120016033 | Small Molecule Antagonists of Phosphatidylinositol-3,4,5-Triphosphate (PIP3) and Uses Thereof - Disclosed are new members of a class of non-lipid small molecule inhibitors which interfere with the interaction between phosphoinositol-3,4,5-triphosphate (PIP3) and pleckstrin homology (PH) domains. These molecules target a broad range of PIP3-dependent signaling events in vitro and exert significant anti-tumor activity in vivo, with improved activity and selectivity toward particular PH domains. The small molecule inhibitors of the invention can be used alone or together with tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) or other cancer medicament to treat cancer. Small molecule inhibitors of the invention act synergistically in combination with TRAIL and with other Akt inhibitors in treating cancer. Pharmaceutical compositions and methods for treating cancer are provided. | 01-19-2012 |
| 20120149778 | COMPOUNDS - The invention provides compounds according to formula (I): (wherein X, Y, Z1 R1, R2, R3, Ar and Ar′ are as defined herein), and physiologically acceptable salts, solvates, esters or amides thereof, pharmaceutical compositions comprising these compounds and the compounds for use in medicine, for example for the treatment or prophylaxis of diseases involving cell proliferation, such as cancer, and for the treatment or prophylaxis of other diseases. | 06-14-2012 |
| 20140187639 | Small Molecule Antagonists of Phosphatidylinositol-3,4,5-Triphosphate (PIP3) and Uses Thereof - Disclosed are new members of a class of non-lipid small molecule inhibitors which interfere with the interaction between phosphoinositol-3,4,5-triphosphate (PIP3) and pleckstrin homology (PH) domains. These molecules target a broad range of PIP3-dependent signaling events in vitro and exert significant anti-tumor activity in vivo, with improved activity and selectivity toward particular PH domains. The small molecule inhibitors of the invention can be used alone or together with tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) or other cancer medicament to treat cancer. Small molecule inhibitors of the invention act synergistically in combination with TRAIL and with other Akt inhibitors in treating cancer. Pharmaceutical compositions and methods for treating cancer are provided. | 07-03-2014 |
| 514585000 | Benzene ring containing | 10 |
| 20090005452 | Diphenyl Urea Derivatives - The invention relates to novel specifically trifluoromethyl and halogen substituted 1,3-diphenyl ureas and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects like the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as anti-infectives. | 01-01-2009 |
| 20130190405 | METHODS AND USE OF COMPOUNDS THAT BIND TO HER2/NEU RECEPTOR COMPLEX - This application describes pharmaceutical compositions, kits, and methods for inhibiting cell proliferative disorders, especially those disorders characterized by overactivity and/or inappropriate activity of a receptor tyrosine kinase, including Her2 related cancers, and methods for imaging an Her-2 expressing tumor. | 07-25-2013 |
| 514586000 | Nitrogen attached indirectly to the -C(=S)-group by nonionic bonding | 6 |
| 20080255238 | COMPOSITION CONTAINING A THIOUREA DERIVATIVE FOR PREVENTING OR TREATING PRURITIC OR IRRITANT SKIN DISEASES - Disclosed herein is a composition for preventing or treating pruritic or irritant skin diseases which comprises, as a vanilloid receptor antagonist, a thiourea derivative, a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof, together with a pharmaceutically acceptable carrier. | 10-16-2008 |
| 20090118374 | SULFONAMIDO COMPOUNDS THAT ANTAGONISE THE VANILLOID TRPV1 RECEPTOR - The invention relates to sulfonamido derivatives of formula (I) | 05-07-2009 |
| 20090215902 | METHODS FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS - The present invention is directed to the use of a compound of formula (I) | 08-27-2009 |
| 20090253799 | DIVALENT HYDRAZIDE COMPOUND CONJUGATES FOR INHIBITING CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR - Provided herein are divalent hydrazide-polyethylene glycol conjugates that inhibit the ion transport activity of a cystic fibrosis transmembrane conductance regulator (CFTR). The conjugates described herein are useful for treating diseases, disorders, and sequelae of diseases, disorders, and conditions that are associated with aberrantly increased CFTR activity, for example, secretory diarrhea. | 10-08-2009 |
| 20120283330 | METHODS FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS - The present invention is directed to the use of a compound of formula (I) | 11-08-2012 |
| 20120322877 | (BIS)UREA AND (BIS)THIOREA COMPOUNDS AS EIPGENIC MODULATORS OF LYSINE-SPECIFIC DEMETHYLASE 1 AND METHODS OF TREATING DISORDERS - The invention provides for novel (bis)urea and (bis)thiourea compounds which are inhibitors of lysine-specific demethylase 1 (LSD1). Such compounds may be used to treat disorders, including cancer. | 12-20-2012 |
| 514587000 | Oxygen containing | 2 |
| 20100093864 | ANTI-INFECTIVE THIOUREA COMPOUNDS - The present application discloses thiourea compounds for use in the treatment of infections. The thiourea compounds have formula (I) wherein X | 04-15-2010 |
| 20130203852 | METHODS OF CONTROLLING NEONICOTINOID RESISTANT APHIDS - The invention relates to a method of controlling aphids that are resistant to neonicotinoid insecticides, using the compound diafenthiuron in free form or in agrochemically acceptable salt form as well as the use of compositions comprising said compound to control neonicontinoid resistant insects. In particular the methods relate to controlling neonicotinoid resistant insects in the Aphididae family, that are resistant to one or more neonicotinoid insecticides. Methods of the invention find particular use in controlling neonicotinoid resistant insects in crops of useful plants. Furthermore, the invention extends to methods of controlling plant viruses spread by neonicotinoid resistant insects. | 08-08-2013 |
